<DOC>
	<DOCNO>NCT02696044</DOCNO>
	<brief_summary>The aim study evaluate safety tolerability triheptanoin participant Rett syndrome use laboratory value , electrocardiogram , rate adverse event ( AE ) , physical exam.This study also seek evaluate efficacy UX007 ( triheptanoin ) improve overall seizure frequency dystonia .</brief_summary>
	<brief_title>Treatment Mitochondrial Dysfunction Rett Syndrome With Triheptanoin</brief_title>
	<detailed_description>The aim study evaluate safety tolerability triheptanoin participant Rett syndrome use laboratory value , electrocardiogram , rate adverse event ( AE ) , physical exam . This study also seek evaluate efficacy UX007 ( triheptanoin ) improve overall seizure frequency , dystonia severity , quality life . Participants eligible take triheptanoin daily . Participation study last 8.5 month .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Rett Syndrome</mesh_term>
	<criteria>Diagnosis Classic Rett syndrome define clinical consensus criterion Presence MECP2 mutation Postregression stage development , define great 6 month since last loss hand use verbal language Average least 4 observable seizure ( generalize partialonset [ Generalized TonicClonic , Generalized Tonic , Generalized Clonic , Generalized Atonic , Partial/Focal Secondary Generalization , Myoclonic , Myoclonic Atonic , Myoclonic Tonic , Complex Partial/Focal , Simple Partial/Focal Motor ) one month prior study caregiver report presence dystonia average least four time one month prior study least one body region rat least `` mild '' caregiver report Use least one antiseizure medication screen visit At screen visit , manage four few concomitant antiseizure medication must stable dose least one month prior begin screen anticipated remain stable dose end 8.5 month trial period Legally authorize caregiver must willing give write informed consent nature study explain , prior researchrelated procedure Caregiver participant must , opinion investigator , willing able complete aspect study , comply accurate completion seizure dystonia diary , likely complete four month treatment period Markedly abnormal metabolic screen laboratory testing ( e.g. , serum alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) level exceed 2X upper limit normal ) Any known hypersensitivity triheptanoin , judgment investigator , place subject increase risk adverse effect Prior use triheptanoin within 1 month prior screen Participants caregiver unwilling unable discontinue use prohibit medication substance may confound study objective Use investigational product , include drug supplement within 1 month prior Screening , time study Has condition severity acuity , opinion investigator , warrant immediate surgical intervention treatment Has concurrent disease condition , laboratory abnormality , view investigator , place subject high risk poor treatment compliance complete study , would interfere study participation introduces additional safety concern ( e.g. , diabetes mellitus ) Pregnant nursing woman</criteria>
	<gender>Female</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Gastrointestinal Disorders</keyword>
</DOC>